efinopegdutide   Click here for help

GtoPdb Ligand ID: 14750

Synonyms: HM-12525A | HM12525A | JNJ-64565111 | JNJ64565111 | LAPS-GLP-1/GCG | MK-6024 | MK6024
Compound class: Peptide
Comment: Efinopegdutide (MK-6024, formerly HM-12525A and JNJ-64565111) is a once-weekly injectable, dual agonist of the GLP-1 and glucagon receptors [3]. Structurally is a conjugate of an oxyntomodulin analogue and the constant region (Fc) of human IgG4, joined via a 10 kDa polyethylene glycol (PEG) linker. The INN record shows that the amino acid sequence of the oxyntomodulin analogue component is HBQGTFTSDYSKYLDEKRAKEFVQWLMNTC-NH2, where B2 is 2-methylalanyl (2-aminoisobutyryl, Aib). An amide bond between E and K cyclises the peptide.
No information available.
Summary of Clinical Use Click here for help
As JNJ-64565111, efinopegdutide was progressed as an anti-diabetes/anti-obesiy clinical candidate [1-2,5]. It was subsequently evaluated for potential to reduce liver fat content in patients with metabolic dysfunction-associated steatohepatitis (MASH) [7,9].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04944992 A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) Phase 2 Interventional Merck Sharp & Dohme LLC 8
NCT05877547 A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) Phase 2 Interventional Merck Sharp & Dohme LLC 4
NCT03586830 A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus Phase 2 Interventional Janssen Research & Development, LLC 2